Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Frankfurt - Delayed Quote EUR

Veru Inc. (FMW.F)

Compare

0.4898

-0.0432

(-8.11%)

As of 8:08:23 AM GMT+1. Market Open.

3 US Penny Stocks With Market Caps Under $300M To Consider

The U.S. stock market recently experienced a sharp decline after two days of record highs for the S&P 500, with major indices like the Dow Jones and Nasdaq also seeing significant drops. For investors interested in smaller or newer companies, penny stocks remain a relevant area of investment despite their vintage name. These stocks, often representing firms with solid financial foundations, can offer unique opportunities for growth and value that larger companies might overlook.

Simply Wall St. 5 days ago

ISPR

VERU

CLAR
Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...

Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles and strategic divestments.

GuruFocus.com 12 days ago

VERU
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function-- -- The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed-- --Topline results of the Phase 2b extension m

GlobeNewswire 13 days ago

VERU
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, February 13, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 first quarter financial results and to provide a business update. The audio webca

GlobeNewswire 19 days ago

VERU
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 1

GlobeNewswire 21 days ago

VERU
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less lean mass than patients receiving WEGOVY alone -- -- Patients on Enobosarm on average lost 27% more fat mass than patients receiving WEGOVY alone – -- Enobosarm improved body composition as mean total body weight loss was similar compared to subjects receiving WEGOVY alone -- -- Enob

GlobeNewswire 30 days ago

VERU
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?

Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks last month

VERU
3 US Penny Stocks With Market Caps Under $200M To Consider

The U.S. stock market has shown resilience, with the Dow Jones Industrial Average rising on a softer-than-expected Producer Price Index report and a dip in oil prices. For those interested in exploring smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area. These stocks can offer a mix of affordability and growth potential, especially when backed by strong financials, making them appealing to investors seeking under-the-radar...

Simply Wall St. last month

VERU

TORO

PETS
Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline

Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal Condom) business to clients managed by Riva Ridge Capital Management LP and co-investors for $18 million. As a result of the FC2 business sale, Veru’s workforce will be reduced by approximately 90%, from 210 employees to 22. After deducting the change of control premium to SWK Funding LLC under the company's Residual Royalty Agreement, along with customary transaction fees, Ve

Benzinga last month

VERU
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm as well as other co-investors, fo

GlobeNewswire last month

VERU
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates

Veru (VERU) delivered earnings and revenue surprises of 14.29% and 86.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

VERU
US Penny Stocks To Consider In December 2024

As the U.S. stock market experiences a rise in anticipation of the Federal Reserve's upcoming meeting, with the Nasdaq hitting record highs, investors are exploring diverse opportunities across various sectors. Penny stocks, though often seen as remnants of past market trends, continue to offer intriguing possibilities for those seeking growth at lower entry points. By focusing on smaller or newer companies with strong financials and potential for expansion, investors can uncover valuable...

Simply Wall St. 2 months ago

DLTH

VERU

FSI
The past three years for Veru (NASDAQ:VERU) investors has not been profitable

As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So consider, for...

Simply Wall St. 2 months ago

VERU
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders, taking place December 6-8, 2024, in Washington, DC. Presentation Name:

GlobeNewswire 2 months ago

VERU
Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas. Highlights from the presentation:The objective of the meta-analysis was to determine the eff

GlobeNewswire 3 months ago

VERU
Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at ObesityWeek, taking place November 3-6, 2024, in San Antonio, Texas. Presentation Name: Meta-analysis of subjects from 4 randomized clinical trials supports the potential o

GlobeNewswire 4 months ago

VERU
Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present at the World Obesity and Weight Management Congress, taking place October 24-26, 2024, in Baltimore, Maryland. Keynote Presentation Name: Advancing enobosarm, an oral novel Se

GlobeNewswire 4 months ago

VERU
Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...

Veru Inc (VERU) reports increased net revenue and reduced operating expenses, while navigating challenges in its US prescription business and advancing clinical trials.

GuruFocus.com 4 months ago

VERU
Veru to Present at the 2024 Cantor Global Healthcare Conference

MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present a corporate update with a focus on the progress of Veru’s Phase 2b clinical development program of enobos

GlobeNewswire 5 months ago

VERU
Earnings Beat: Veru Inc. (NASDAQ:VERU) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Veru Inc. ( NASDAQ:VERU ) came out with its quarterly results last week, and we wanted to see how the business is...

Simply Wall St. 6 months ago

VERU

Performance Overview

Return	FMW.F	S&P 500
YTD	-23.53%	+1.25%
1-Year	-6.44%	+17.47%
3-Year	-90.35%	+35.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Veru Inc. (FMW.F)

3 US Penny Stocks With Market Caps Under $300M To Consider

Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?

3 US Penny Stocks With Market Caps Under $200M To Consider

Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates

US Penny Stocks To Consider In December 2024

The past three years for Veru (NASDAQ:VERU) investors has not been profitable

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...

Veru to Present at the 2024 Cantor Global Healthcare Conference

Earnings Beat: Veru Inc. (NASDAQ:VERU) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Performance Overview